Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer: M.D. Anderson Cancer center off label experience

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 1, 2015, Pages E77-E81

  Dadu, Ramona ^a   Shah, Komal ^b   Busaidy, Naifa L ^a   Waguespack, Steven G ^a   Habra, Mouhammad A ^a   Ying, Anita K ^a   Hu, Mimi I ^a   Bassett, Roland ^a   Jimenez, Camilo ^a   Sherman, Steven I ^a   Cabanillas, Maria E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Departments of Diagnostic Radiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; THYROGLOBULIN; TRIACYLGLYCEROL LIPASE; VALINE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ARTICLE; BLISTER; BLURRED VISION; CALLUS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; DIARRHEA; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FEVER; GINGIVA DISEASE; HAIR LOSS; HAND FOOT SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HOARSENESS; HUMAN; HYPERTENSION; KERATOSIS; MALE; MELANOCYTIC NEVUS; MUCOSA INFLAMMATION; MUTATION; NAIL DISEASE; NAUSEA; NECK CANCER; PALMAR WART; PAPILLARY THYROID CANCER; PHOTOSENSITIVITY; PRURITUS; QT PROLONGATION; RASH; RETROSPECTIVE STUDY; SKIN CARCINOMA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME; UVEITIS; VERRUCA VULGARIS; VERRUCOUS KERATOSIS; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA; AGED; CARCINOMA; GENETICS; MIDDLE AGED; OFF LABEL DRUG USE; PATHOLOGY; THYROID NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OFF-LABEL USE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SULFONAMIDES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84920598146     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2246     Document Type: Article

References (19)

1. Durante C, Haddy N, Baudin E, et al. Long-term ou tcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
2. Elisei R, Ugolini C, Viola D, et al. Braf(v600e) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3949.
3. Xing M. Braf mutati on in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
4. Durante C, Puxeddu E, Ferretti E, et al. Braf mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840-2843.
5. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328.
6. Falchook GS,Long GV,Kurzrock R,Kim KB,Arkenau TH,Brown MP,et al. Dabrafenib in patients with melanoma, unt reated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet. 2012 379 1893-1901
7. Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013;23:1277-1283.
8. Brose MS, Cabanillas ME, Cohen EE, et al. An open-label, multicenter phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF v600 mutation an d resistant to radioactive iodine. Proceedings of the European Cancer Congress, Amsterdam, 2013. 2013;oral abstr 28.
9. Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8:1228-1274.
10. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guid elines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to trea tment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
12. Eis enhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
13. Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31-42.
14. Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014;24:918-922.
15. D adu R, Shah K, Bassett R, et al. Is there an alternative treatment option for patients with advanced papillary thyroid cancer (PTC) harboring the brafv600e mutation? ICE/ENDO Meeting. 2014.
16. Dadu R, Devin e C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014;99:2086-2094.
17. Rothenberg SM, McFadden DG, Palmer E, et al.Re-differentiation of radioiodine-refractory BRAFV600E-mutant thyroid carcinoma with dabrafenib: A pilot study. J Clin Oncol. 2013;31;(suppl; abstr 6025).
18. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.NEngl J Med. 2013;368: 623-632.
19. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with braf v600e mutation.NEngl J Med. 2011;364:2507-2516.